Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to: